Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
Eli Lilly’s $1.925 Billion Acquisition of Versanis Bio
Evelo Biosciences’ $25.5 Million Private Placement
Goodwin advised Flagship Pioneering on the investment. Evelo Biosciences, Inc. (Nasdaq:EVLO) announced a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of...
ReNAgade Therapeutics’ $300 Million Series A Financing Round
Goodwin advised ReNAgade Therapeutics on the fundraising. ReNAgade Therapeutics announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has...
ElevateBio’s $401 Million Series D Financing Round
Goodwin advised ElevateBio on the financing. ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
Quest Diagnostics’ Acquisition of Haystack Oncology
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
Avadel’s $96 Million Exchange of Convertible Notes
Goodwin advised Avadel on the deal. Avadel extended the maturity of $96.2 million of its convertible notes to 2027. Under the terms of the convertible note exchange...
Avadel Pharmaceuticals’ $75 Million Royalty Financing
Goodwin Procter advised Avadel Pharmaceutics on the deal. Avadel announced its royalty agreement with RTW Investments, LP and certain of its affiliates for up to $75 million....
Avadel Pharmaceutics’ $125 Million follow-on Equity Offering
Goodwin Procter advised Avadel Pharmaceutics plc on the deal. Avadel Pharmaceuticals announced an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per...
OncoC4’s Strategic Collaboration with BioNTech
Goodwin advised OncoC4 on the deal. OncoC4 announced its agreement with BioNTech SE pursuant to which BioNTech receives an exclusive worldwide license to co-develop and commercialize OncoC4’s...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
TPI Composites’ $132.5 Million Convertible Notes Offering
Goodwin Procter advised TPI Composites, Inc. on the deal. Davis Polk advised the representative of the initial purchasers and the counterparties to the capped call transactions...